home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
  HUM-MOLGEN -> Events -> Meetings and Conferences  
 

Development of Type 2 Diabetes Mellitus Drugs: State of the Art Cardiovascular Safety Assessments

 
  June 13, 2010  
     
 
L’Enfant Plaza Hotel, Washington, DC, USA
Oct 5 2010 8:00AM - Oct 6 2010 5:00PM


CALL FOR ABSTRACTS
Please submit all abstracts via email to Rachel Minnick, Program Developer
Rachel.Minnick@diahome.org
All abstracts must be received by August 17, 2010.
Please provide all information in PowerPoint or MSWord format

This two-day conference will examine:
• How to more efficiently develop T2DM medications
• How to evaluate CV safety during DM drug development – preclinical and clinical approaches
• Clinical implications and benefi ts of glycemic control
• Therapies and targets for treatment of Diabetes Mellitus
• Evidence for positive and negative impacts on CV and renal outcomes in Type 2 DM
• Novel trial design approaches to assessing CV safety
• Clinical evidence that T2DM diabetic drugs can increase CV risk and potential mechanisms
• Approaches to the clinical analysis of CV risk
• Clinical approaches to Phase 3 development
• Future approaches to assessing T2DM drug development and CV safety
• Preclinical studies and the use of biomarkers to assess CV safety of new chemical entities


Event Code:
10035

 
 
Organized by: DIA
Invited Speakers: Call contact
 
Deadline for Abstracts: 08/17/2010
 
Registration: For further information, contact
Rachel Minnick, Program Developer
Phone +1.215.442.6131
Fax +1.215.293.5904
email
Rachel.Minnick@diahome.org
E-mail: Rachel.Minnick@diahome.org
 
   
 
home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
 
 

Generated by meetings and positions 5.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995- HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.